Annexon competitors

Clive Richardson is a Board Member at Akari Therapeutics PLC. He has worked as Head:Operations at Volution Immuno Pharmaceuticals SA, Board Member at CLINISYS SOLUTIONS LIMITED, and Interim CEO/COO at Akari Therapeutics PLC. Clive works or has worked as Head:Equities Research at Investec. He attended Trinity College Oxford.

Michael S. Weiss has served as the Company’s Executive Chairman, President and CEO since December 2011. Mr. Weiss is also currently a director of the Company. Mr. Weiss is a co-founder of, and has been a Managing Partner and Principal of Opus Point Partners since 2008. Mr. Weiss has also been the Executive Chairman, Strategic Development of Fortress Biotechnology since January 2014 and has served as Co-Vice Chairman of the Fortress Biotech Board of Directors since December 2013. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore. In 1999, Mr. Weiss founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Following the merger, Mr. Weiss remained as CEO of Keryx and grew the company to close to a $1BB market capitalization company at its peak. While at Keryx, he raised over $150MM in equity capital through public and private offerings, executed a $100MM+ strategic alliance, negotiated multiple Special Protocol Assessments (“SPA”) agreements with the FDA and managed multiple large clinical trials.

Founder Aedio • Worked at @massachusetts-general-hospital-mgh, @brigham-women-s-hospital • Studied at @tufts-university

James Fairbairn has 20+ years in senior finance roles with emerging companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim holds a Bachelor of Arts from the University of Western Ontario. He is a director of several junior listed companies.